Oncosec Medical Inc (ONCS) 0.3800 $ONCS
OncoSec Medical to Present at Two Events in February
Business Wire - Tue Feb 03, 5:03AM CST
OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that it will present at two high-profile scientific and investment conferences in February.
The Market for Personalized Gene Therapy Treatments for Cancer
M2 - Fri Jan 16, 8:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/9ddkrc/the_market_for) has announced the addition of the "The Market for Personalized Gene Therapy Treatments for Cancer" report to their offering. This report, The Market for Personalized Gene Therapy Treatments For Cancer provides an exhaustive review of the market potential for relatively new approach in cancer research. It involves modification of genes instead of using a surgical method or chemical drug product. Essentially, gene therapies replace an abnormal gene with a normal gene, or changes the response of a gene (turn on or off). Not all of the approaches to gene therapy are the same, and different cancers appear to respond better to different therapies. Several gene therapy technologies have the ability to work in combination with other treatment options to enhance the effectiveness of a therapeutic regimen. Gene therapy is also designed to target specific cells making treatment much less damaging to healthy cells. This report discusses those treatments and estimates market size and market potential for personalized medicine using gene therapy. In addition the report provides: - Overview of Gene Therapy - Overall Market Size and Forecast - Cancer Therapeutic Market Totals - Discussion of Somati vs. Germ Line Gene Therapy - R&D Activities - Company Profiles Key Topics Covered: - Executive Summary - Gene Therapy Overview - Cancer and Gene Therapy - Gene Therapy Outlook in Bladder Cancer - Gene Therapy Outlook in Brain Cancer - Gene Therapy Outlook in Breast Cancer - Gene Therapy Outlook in Colorectal Cancer - Gene Therapy Outlook in Head & Neck Cancer - Gene Therapy Outlook in Leukemia - Gene Therapy Outlook in Liver Cancer - Gene Therapy Outlook in Lung Cancer - Gene Therapy Outlook in Lymphoma - Gene Therapy Outlook in Melanoma - Gene Therapy Outlook in Ovarian Cancer - Gene Therapy Outlook in Pancreatic Cancer - Gene Therapy Outlook in Prostate Cancer - Gene Therapy and Other Cancers - Gene Therapy in Cancer Market Summary and Outlook - Industry Participants and Contributors Companies Mentioned - Advantagene, Inc. - Amgen, Inc. - Bellicum Pharmaceuticals, Inc. - BioCancell Ltd. - Blubird Bio - Celgene - Celsion Corporation - Chengdu Shi Endor Biological Engineering Technology Co., Ltd. - Cold Genesys, Inc. - Genprex, Inc. - MaxiVax SA - Momotaro-Gene, Inc. - MultiVir, Inc. - OncoSec Medical, Inc. - Sevion Therapeutics, Inc. - SynerGene Therapeutics, Inc. - Takara Bio, Inc. - Tocagen, Inc. - VBL Therapeutics Ltd. - Ziopharm Oncology, Inc. - daptimmune Ltd. For more information visit http://www.researchandmarkets.com/research/9d...market_for
CLSN: 2.41 (+0.09), BLCM: 20.00 (-0.81), AMGN: 153.48 (+0.30), CELGZ: 3.17 (-0.04)
OncoSec Medical announces USPTO patent allowance for intratumoral delivery of plasmid IL-15
M2 - Wed Jan 14, 6:59AM CST
Cancer immunotherapies company OncoSec Medical (OTCQB:ONCS) said on Tuesday that the US Patent and Trademark Office (USPTO) has approved claims covering a method of treating cancerous tumors with plasmid-encoded IL-15 and electroporation therapy to the tumor having a field strength of at least 700 V/cm.
Vista Partners Initiates Coverage on OncoSec Medical (Ticker: ONCS); Price Target $1.20
Marketwired - Tue Jan 13, 8:02AM CST
Vista Partners announced today that it has initiated coverage on OncoSec Medical Inc. (OTCQB: ONCS) ("the Company"
based in San Diego, CA, with a twelve month price target of $1.20. Ross Silver, Principal Analyst at Vista Partners, stated, "ONCS entered into a clinical collaboration with the University of California, San Francisco (UCSF), to evaluate the safety, tolerability and efficacy of the combination of KEYTRUDA(R) (pembrolizumab), Merck's anti-PD-1 therapy, and OncoSec's ImmunoPulse (intratumoral IL-12) in metastatic melanoma. Recent data suggest that patients who are PD-L1 positive and have increased tumor-infiltrating lymphocytes (TILs) are more likely to respond to anti-PD-1/PD-L1 mAbs compared to patients who are PD-L1 negative. Therefore, therapies that promote TIL generation and PD-L1 positivity may play an important role in augmenting the clinical efficacy of these agents."
MRK: 58.81 (-0.07)
OncoSec Medical Obtains Allowance of Key Patent Application for Intratumoral Delivery of Plasmid IL-15
Business Wire - Tue Jan 13, 5:02AM CST
OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announces that the United States Patent and Trademark Office (USPTO) has allowed claims covering a method of treating cancerous tumors with plasmid-encoded IL-15 and electroporation therapy to the tumor having a field strength of at least 700 V/cm. This announcement enhances OncoSec's IP portfolio and provides significant support to the ongoing expansion of its immuno-oncology pipeline.
OncoSec Medical Plans to Initiate Pilot Study in Triple Negative Breast Cancer
Business Wire - Mon Jan 12, 5:02AM CST
OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, plans to initiate a pilot study to assess IL-12 ImmunoPulse in patients with Triple Negative Breast Cancer (TNBC). The study will be conducted at Stanford University with Melinda L. Telli, MD, serving as lead investigator.
OncoSec Medical to Present at Three Events in January
Business Wire - Wed Jan 07, 5:02AM CST
OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will present at three events in January. The Company's agenda includes a number of high-profile scientific and investment conferences.
OncoSec to start Phase 2 study in SCCHN
Seeking Alpha - at Seeking Alpha - Tue Dec 09, 11:52AM CST
OncoSec Medical Announces New Phase II Trial in Head and Neck Cancer Using ImmunoPulse
Business Wire - Tue Dec 09, 5:02AM CST
OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, has initiated a Phase II trial in squamous cell carcinoma of the head and neck (SCCHN) using its proprietary ImmunoPulse platform. The multicenter study is scheduled to be initiated in the first quarter of 2015, with the University of California San Francisco, under the direction of Dr. Alain Algazi as the first site of enrollment.
OncoSec Medical Announces First Quarter Results for Fiscal Year End 2015
Business Wire - Mon Dec 08, 5:02AM CST
OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced financial results for the quarter ended October 31, 2014.
OncoSec reports Phase 2 ImmunoPulse data in melanoma
Seeking Alpha - at Seeking Alpha - Fri Dec 05, 11:48AM CST
MRK: 58.81 (-0.07)
OncoSec schedules corporate update
Seeking Alpha - at Seeking Alpha - Fri Dec 05, 7:33AM CST
OncoSec Medical to Host Corporate Update Conference Call on December 9, 2014
Business Wire - Fri Dec 05, 5:02AM CST
OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will host a corporate update conference call on Tuesday, December 9, 2014 at 10 AM ET. The call will cover recent milestone achievements and corporate and clinical development strategies, but will not address the company's results of operations or financial condition for a completed quarterly or annual fiscal period. To participate in the call, dial toll-free (855) 801-3670 in the U.S. and Canada or (804) 681-3878 outside the U.S. and Canada and enter conference ID #48289768.
OncoSec Reports ImmunoPulse May Prolong Survival Based on Analysis of Long-Term Survival Data from Phase I Study in Melanoma
Business Wire - Thu Dec 04, 11:00AM CST
OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based cancer immunotherapies, released long-term survival results from its Phase I study in patients with metastatic melanoma, evaluating a single treatment cycle of intratumoral plasmid IL-12 (pIL-12) injection with electroporation (EP). Dr. Robert Pierce, Chief Scientific Officer at OncoSec, a co-author of the abstract presented these data today at the Melanoma Bridge 2014 conference in Naples, Italy.
OncoSec Medical Collaborates with PerkinElmer and University of California, Los Angeles to Evaluate Patient-Selection Biomarker in Immunotherapy
Business Wire - Tue Dec 02, 5:02AM CST
OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced a collaboration with PerkinElmer, Inc. and the University of California, Los Angeles (UCLA) to help researchers develop biomarker tests to evaluate a patient's immune response to cancer. This research supports the ongoing shift in oncology toward therapeutic strategies that stimulate the patient's own immune defense system to combat cancer. The approach uses PerkinElmer's new imaging-based staining methods to quantitatively evaluate CD8+ T cell density in tumor biopsies.
MRK: 58.81 (-0.07), PKI: 46.30 (-0.10)
OncoSec Medical to Present at Two Events in December
Business Wire - Fri Nov 28, 5:02AM CST
OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will present at two events in December. The Company's agenda includes high-profile scientific and investment conferences, coming on the heels of a recent key milestone announcement.
Nature Publication Co-Authored by Robert H. Pierce, Chief Scientific Officer, OncoSec Medical
Business Wire - Wed Nov 26, 12:43PM CST
Research conducted by Robert H. Pierce, MD, Chief Scientific Officer at OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, was published in the November 27, 2014 issue of the journal Nature. The publication, titled "PD-1 blockade induces responses by inhibiting adaptive immune resistance," presents research led by Drs. Paul Tumeh, MD and Antoni Ribas, MD at the University of California, Los Angeles (UCLA), with studies conducted by Dr. Pierce and colleagues at Merck Research Labs, during his previous tenure as Executive Director at Merck. The results provide OncoSec with supporting evidence that response to anti-PD-1 drugs such as Merck's breakthrough drug KEYTRUDA(R) (pembrolizumab) is dependent on the presence of PD-L1 and tumor-infiltrating lymphocytes (TILs) in the tumor.
OncoSec and UCSF team up in clinical collaboration
Seeking Alpha - at Seeking Alpha - Tue Nov 25, 12:42PM CST
MRK: 58.81 (-0.07)
UC San Francisco and OncoSec Medical Collaborate to Evaluate Investigational Combination of ImmunoPulse and Anti-PD-1 Treatment
Business Wire - Tue Nov 25, 2:01AM CST
OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, has entered a clinical collaboration with the University of California, San Francisco (UCSF), to evaluate the safety, tolerability and efficacy of the combination of KEYTRUDA(R) (pembrolizumab), Merck's anti-PD-1 therapy, and OncoSec's ImmunoPulse (intratumoral IL-12) in metastatic melanoma.
MRK: 58.81 (-0.07)
OncoSec Medical and the University of Washington Enter Sponsored Research Agreement
Business Wire - Thu Nov 20, 5:02AM CST
OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, has entered a Sponsored Research Agreement (SRA) with the University of Washington to evaluate the immunologic mechanisms of intratumoral DNA IL-12 electroporation.
OncoSec Medical to Present at Two Events in February
Business Wire - Tue Feb 03, 5:03AM CST
OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that it will present at two high-profile scientific and investment conferences in February.
The Market for Personalized Gene Therapy Treatments for Cancer
M2 - Fri Jan 16, 8:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/9ddkrc/the_market_for) has announced the addition of the "The Market for Personalized Gene Therapy Treatments for Cancer" report to their offering. This report, The Market for Personalized Gene Therapy Treatments For Cancer provides an exhaustive review of the market potential for relatively new approach in cancer research. It involves modification of genes instead of using a surgical method or chemical drug product. Essentially, gene therapies replace an abnormal gene with a normal gene, or changes the response of a gene (turn on or off). Not all of the approaches to gene therapy are the same, and different cancers appear to respond better to different therapies. Several gene therapy technologies have the ability to work in combination with other treatment options to enhance the effectiveness of a therapeutic regimen. Gene therapy is also designed to target specific cells making treatment much less damaging to healthy cells. This report discusses those treatments and estimates market size and market potential for personalized medicine using gene therapy. In addition the report provides: - Overview of Gene Therapy - Overall Market Size and Forecast - Cancer Therapeutic Market Totals - Discussion of Somati vs. Germ Line Gene Therapy - R&D Activities - Company Profiles Key Topics Covered: - Executive Summary - Gene Therapy Overview - Cancer and Gene Therapy - Gene Therapy Outlook in Bladder Cancer - Gene Therapy Outlook in Brain Cancer - Gene Therapy Outlook in Breast Cancer - Gene Therapy Outlook in Colorectal Cancer - Gene Therapy Outlook in Head & Neck Cancer - Gene Therapy Outlook in Leukemia - Gene Therapy Outlook in Liver Cancer - Gene Therapy Outlook in Lung Cancer - Gene Therapy Outlook in Lymphoma - Gene Therapy Outlook in Melanoma - Gene Therapy Outlook in Ovarian Cancer - Gene Therapy Outlook in Pancreatic Cancer - Gene Therapy Outlook in Prostate Cancer - Gene Therapy and Other Cancers - Gene Therapy in Cancer Market Summary and Outlook - Industry Participants and Contributors Companies Mentioned - Advantagene, Inc. - Amgen, Inc. - Bellicum Pharmaceuticals, Inc. - BioCancell Ltd. - Blubird Bio - Celgene - Celsion Corporation - Chengdu Shi Endor Biological Engineering Technology Co., Ltd. - Cold Genesys, Inc. - Genprex, Inc. - MaxiVax SA - Momotaro-Gene, Inc. - MultiVir, Inc. - OncoSec Medical, Inc. - Sevion Therapeutics, Inc. - SynerGene Therapeutics, Inc. - Takara Bio, Inc. - Tocagen, Inc. - VBL Therapeutics Ltd. - Ziopharm Oncology, Inc. - daptimmune Ltd. For more information visit http://www.researchandmarkets.com/research/9d...market_for
CLSN: 2.41 (+0.09), BLCM: 20.00 (-0.81), AMGN: 153.48 (+0.30), CELGZ: 3.17 (-0.04)
OncoSec Medical announces USPTO patent allowance for intratumoral delivery of plasmid IL-15
M2 - Wed Jan 14, 6:59AM CST
Cancer immunotherapies company OncoSec Medical (OTCQB:ONCS) said on Tuesday that the US Patent and Trademark Office (USPTO) has approved claims covering a method of treating cancerous tumors with plasmid-encoded IL-15 and electroporation therapy to the tumor having a field strength of at least 700 V/cm.
Vista Partners Initiates Coverage on OncoSec Medical (Ticker: ONCS); Price Target $1.20
Marketwired - Tue Jan 13, 8:02AM CST
Vista Partners announced today that it has initiated coverage on OncoSec Medical Inc. (OTCQB: ONCS) ("the Company"
based in San Diego, CA, with a twelve month price target of $1.20. Ross Silver, Principal Analyst at Vista Partners, stated, "ONCS entered into a clinical collaboration with the University of California, San Francisco (UCSF), to evaluate the safety, tolerability and efficacy of the combination of KEYTRUDA(R) (pembrolizumab), Merck's anti-PD-1 therapy, and OncoSec's ImmunoPulse (intratumoral IL-12) in metastatic melanoma. Recent data suggest that patients who are PD-L1 positive and have increased tumor-infiltrating lymphocytes (TILs) are more likely to respond to anti-PD-1/PD-L1 mAbs compared to patients who are PD-L1 negative. Therefore, therapies that promote TIL generation and PD-L1 positivity may play an important role in augmenting the clinical efficacy of these agents." MRK: 58.81 (-0.07)
OncoSec Medical Obtains Allowance of Key Patent Application for Intratumoral Delivery of Plasmid IL-15
Business Wire - Tue Jan 13, 5:02AM CST
OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announces that the United States Patent and Trademark Office (USPTO) has allowed claims covering a method of treating cancerous tumors with plasmid-encoded IL-15 and electroporation therapy to the tumor having a field strength of at least 700 V/cm. This announcement enhances OncoSec's IP portfolio and provides significant support to the ongoing expansion of its immuno-oncology pipeline.
OncoSec Medical Plans to Initiate Pilot Study in Triple Negative Breast Cancer
Business Wire - Mon Jan 12, 5:02AM CST
OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, plans to initiate a pilot study to assess IL-12 ImmunoPulse in patients with Triple Negative Breast Cancer (TNBC). The study will be conducted at Stanford University with Melinda L. Telli, MD, serving as lead investigator.
OncoSec Medical to Present at Three Events in January
Business Wire - Wed Jan 07, 5:02AM CST
OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will present at three events in January. The Company's agenda includes a number of high-profile scientific and investment conferences.
OncoSec to start Phase 2 study in SCCHN
Seeking Alpha - at Seeking Alpha - Tue Dec 09, 11:52AM CST
OncoSec Medical Announces New Phase II Trial in Head and Neck Cancer Using ImmunoPulse
Business Wire - Tue Dec 09, 5:02AM CST
OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, has initiated a Phase II trial in squamous cell carcinoma of the head and neck (SCCHN) using its proprietary ImmunoPulse platform. The multicenter study is scheduled to be initiated in the first quarter of 2015, with the University of California San Francisco, under the direction of Dr. Alain Algazi as the first site of enrollment.
OncoSec Medical Announces First Quarter Results for Fiscal Year End 2015
Business Wire - Mon Dec 08, 5:02AM CST
OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced financial results for the quarter ended October 31, 2014.
OncoSec reports Phase 2 ImmunoPulse data in melanoma
Seeking Alpha - at Seeking Alpha - Fri Dec 05, 11:48AM CST
MRK: 58.81 (-0.07)
OncoSec schedules corporate update
Seeking Alpha - at Seeking Alpha - Fri Dec 05, 7:33AM CST
OncoSec Medical to Host Corporate Update Conference Call on December 9, 2014
Business Wire - Fri Dec 05, 5:02AM CST
OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will host a corporate update conference call on Tuesday, December 9, 2014 at 10 AM ET. The call will cover recent milestone achievements and corporate and clinical development strategies, but will not address the company's results of operations or financial condition for a completed quarterly or annual fiscal period. To participate in the call, dial toll-free (855) 801-3670 in the U.S. and Canada or (804) 681-3878 outside the U.S. and Canada and enter conference ID #48289768.
OncoSec Reports ImmunoPulse May Prolong Survival Based on Analysis of Long-Term Survival Data from Phase I Study in Melanoma
Business Wire - Thu Dec 04, 11:00AM CST
OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based cancer immunotherapies, released long-term survival results from its Phase I study in patients with metastatic melanoma, evaluating a single treatment cycle of intratumoral plasmid IL-12 (pIL-12) injection with electroporation (EP). Dr. Robert Pierce, Chief Scientific Officer at OncoSec, a co-author of the abstract presented these data today at the Melanoma Bridge 2014 conference in Naples, Italy.
OncoSec Medical Collaborates with PerkinElmer and University of California, Los Angeles to Evaluate Patient-Selection Biomarker in Immunotherapy
Business Wire - Tue Dec 02, 5:02AM CST
OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced a collaboration with PerkinElmer, Inc. and the University of California, Los Angeles (UCLA) to help researchers develop biomarker tests to evaluate a patient's immune response to cancer. This research supports the ongoing shift in oncology toward therapeutic strategies that stimulate the patient's own immune defense system to combat cancer. The approach uses PerkinElmer's new imaging-based staining methods to quantitatively evaluate CD8+ T cell density in tumor biopsies.
MRK: 58.81 (-0.07), PKI: 46.30 (-0.10)
OncoSec Medical to Present at Two Events in December
Business Wire - Fri Nov 28, 5:02AM CST
OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will present at two events in December. The Company's agenda includes high-profile scientific and investment conferences, coming on the heels of a recent key milestone announcement.
Nature Publication Co-Authored by Robert H. Pierce, Chief Scientific Officer, OncoSec Medical
Business Wire - Wed Nov 26, 12:43PM CST
Research conducted by Robert H. Pierce, MD, Chief Scientific Officer at OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, was published in the November 27, 2014 issue of the journal Nature. The publication, titled "PD-1 blockade induces responses by inhibiting adaptive immune resistance," presents research led by Drs. Paul Tumeh, MD and Antoni Ribas, MD at the University of California, Los Angeles (UCLA), with studies conducted by Dr. Pierce and colleagues at Merck Research Labs, during his previous tenure as Executive Director at Merck. The results provide OncoSec with supporting evidence that response to anti-PD-1 drugs such as Merck's breakthrough drug KEYTRUDA(R) (pembrolizumab) is dependent on the presence of PD-L1 and tumor-infiltrating lymphocytes (TILs) in the tumor.
OncoSec and UCSF team up in clinical collaboration
Seeking Alpha - at Seeking Alpha - Tue Nov 25, 12:42PM CST
MRK: 58.81 (-0.07)
UC San Francisco and OncoSec Medical Collaborate to Evaluate Investigational Combination of ImmunoPulse and Anti-PD-1 Treatment
Business Wire - Tue Nov 25, 2:01AM CST
OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, has entered a clinical collaboration with the University of California, San Francisco (UCSF), to evaluate the safety, tolerability and efficacy of the combination of KEYTRUDA(R) (pembrolizumab), Merck's anti-PD-1 therapy, and OncoSec's ImmunoPulse (intratumoral IL-12) in metastatic melanoma.
MRK: 58.81 (-0.07)
OncoSec Medical and the University of Washington Enter Sponsored Research Agreement
Business Wire - Thu Nov 20, 5:02AM CST
OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, has entered a Sponsored Research Agreement (SRA) with the University of Washington to evaluate the immunologic mechanisms of intratumoral DNA IL-12 electroporation.
